TrovaGene (TROV) Research Coverage Started at HC Wainwright

HC Wainwright assumed coverage on shares of TrovaGene (NASDAQ:TROV) in a research note released on Thursday, Marketbeat reports. The firm issued a buy rating and a $1.00 price target on the medical research company’s stock.

A number of other research analysts also recently issued reports on TROV. Maxim Group downgraded TrovaGene from a buy rating to a hold rating in a report on Friday, November 10th. downgraded TrovaGene from a buy rating to a hold rating in a report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $3.70.

TrovaGene (NASDAQ:TROV) opened at $0.27 on Thursday. TrovaGene has a twelve month low of $0.24 and a twelve month high of $2.85. The stock has a market capitalization of $10.52, a PE ratio of -0.28 and a beta of 0.35.

TrovaGene (NASDAQ:TROV) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. The company had revenue of $0.12 million for the quarter.

Several hedge funds have recently bought and sold shares of TROV. LMR Partners LLP purchased a new position in shares of TrovaGene during the 2nd quarter worth approximately $151,000. Goldman Sachs Group Inc. grew its holdings in shares of TrovaGene by 1,079.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock worth $351,000 after acquiring an additional 254,601 shares during the period. Finally, Susquehanna International Group LLP grew its holdings in shares of TrovaGene by 2,781.0% during the 2nd quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock worth $174,000 after acquiring an additional 133,240 shares during the period. Hedge funds and other institutional investors own 13.73% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at

About TrovaGene

Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply